更新于：2024-11-04
Doxazosin Mesylate
甲磺酸多沙唑嗪
更新于：2024-11-04
概要
基本信息
原研机构 |
非在研机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C24H29N5O8S |
InChIKeyVJECBOKJABCYMF-UHFFFAOYSA-N |
CAS号77883-43-3 |
关联
84
项与 甲磺酸多沙唑嗪 相关的临床试验甲磺酸多沙唑嗪缓释片（4mg）在中国健康受试者中空腹和餐后给药条件下随机、开放、单剂量、两制剂、两序列、两周期、双交叉生物等效性试验
甲磺酸多沙唑嗪缓释片在健康受试者中单剂量、随机、开放、两周期、两序列、自身交叉、空腹及餐后状态下生物等效性试验
甲磺酸多沙唑嗪缓释片在健康受试者中的随机、开放、单剂量、双周期、自身交叉空腹及餐后生物等效性研究
100 项与 甲磺酸多沙唑嗪 相关的临床结果
登录后查看更多信息
100 项与 甲磺酸多沙唑嗪 相关的转化医学
登录后查看更多信息
100 项与 甲磺酸多沙唑嗪 相关的专利（医药）
登录后查看更多信息
1,785
项与 甲磺酸多沙唑嗪 相关的文献（医药）2024-11-01Heart (British Cardiac Society)
Diagnosis and management of resistant hypertension
Review
作者: Kreutz, Reinhold ; Cho, Myeong-Chan ; Camafort, Miguel
Resistant hypertension is a condition where blood pressure levels remain elevated above target despite changes in lifestyle and concurrent use of at least three antihypertensive agents, including a long-acting calcium channel blocker (CCB), a blocker of the renin-angiotensin system (ACE inhibitor or angiotensin receptor blocker) and a diuretic. To be diagnosed as resistant hypertension, maintaining adherence to therapy is required along with confirmation of blood pressure levels above target by out-of-office blood pressure measurements and exclusion of secondary causes of hypertension. The key management points of this condition include lifestyle changes such as reduced sodium and alcohol intake, regular physical activity, weight loss and discontinuation of substances that can interfere with blood pressure control. It is also recommended that current treatment be rationalised, including single pill combination treatment where antihypertensive drugs should be provided at the maximum tolerated dose. It is further recommended that current drugs be replaced with a more appropriate and less difficult treatment regimen based on the patient’s age, ethnicity, comorbidities and risk of drug–drug interactions. The fourth line of treatment for patients with resistant hypertension should include mineralocorticoid receptor antagonists such as spironolactone, as demonstrated in the PATHWAY-2 trial and meta-analyses. Alternatives to spironolactone include amiloride, doxazosin, eplerenone, clonidine and beta-blockers, as well as any other antihypertensive drugs not already in use. New approaches under research are selective non-steroidal mineralocorticoid receptor antagonists such as finerenone, esaxerenone and ocedurenone, selective aldosterone synthase inhibitors such as baxdrostat, and dual endothelin antagonist aprocitentan.
2024-10-01Journal of pharmacy practice
Safety and Feasibility of Opening Tamsulosin Capsules for Enteral Feeding Tube Administration
Article
作者: Altshuler, Jerry ; Song, Yong-Bum ; Fazio, Victoria
Purpose: Tamsulosin is formulated as sustained release beads within a capsule to prevent rapid absorption and associated hypotension. The package insert advises the capsule is swallowed whole; not crushed, chewed, or opened. To our knowledge, there are no current data on opening capsules for adults with enteral tube feeds. Given the unidentified safety and efficacy of administration via enteral tubes, alternative alpha blockers with less selectivity for alpha1A are often used. Methods: A single center retrospective chart review was conducted at two hospital sites. Adult patients that received at least one dose of tamsulosin or doxazosin while an enteral feeding tube was placed were included. Safety outcomes evaluated were the number of documented tube obstructions and incidence of medication associated hypotension. Results: 169 patients were included. Ten enteral feeding tube obstructions were reported, 4 of 110 (3.64%) in the tamsulosin arm and 6 of 59 (10.17%) in the doxazosin arm (RR .36, 95% CI .11 to 1.22, P = .099). At least 1 episode of medication associated hypotension occurred in 22 of 98 (22.45%) in the tamsulosin arm and 20 of 49 (40.82%) in the doxazosin arm (RR .55, 95% CI .33 to .91, P = .019). Conclusion: There was no statistically significant difference in the number of tube obstructions between patients receiving tamsulosin or doxazosin via enteral tube feeds. Patients receiving doxazosin were at increased risk of experiencing medication related hypotension. Tamsulosin capsules may be opened and administered via enteral feeding tubes if administered with content integrity intact.
2024-09-30International Neurourology Journal
Association Between Alpha-1 Adrenoreceptor Antagonist Use and Cognitive Impairment: A Systematic Review
Article
作者: Gerberi, Dana ; Kingsley, Ryan ; Pagali, Sandeep ; Edquist, Christopher ; Jarsania, Dhairya ; Palmer, Allyson ; Tyree, Sara ; Wilfahrt, Robert
Alpha-1 adrenergic receptor (α1-AR) antagonists are commonly used for management of benign prostatic hyperplasia or hypertension. Some studies have shown a potential link between α1-AR antagonist use and cognitive impairment. Given the conflicting data surrounding α1-AR antagonists association with cognitive dysfunction, we aim to systematically review the association of cognitive dysfunction with α1-AR antagonist use to aid clinician decision both with medication initiation and continuation. A systematic review was performed following PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. We searched Ovid Cochrane, Ovid Embase, Ovid MEDLINE, Scopus, and Web of Science on March 7, 2023, with an update run on January 22, 2024. The primary outcome was cognitive dysfunction. We used Cochrane risk of bias for randomized controlled trials (RCTs) and MINORS (Methodological Index for Non-Randomized Studies) criteria for non-RCTs to evaluate study quality. This study was registered with PROSPERO (CRD42024505751). We identified 7 studies for our systematic review (3 RCTs, 4 non-RCTs). Tamsulosin was the most studied medication (6 of 7 studies). Tamsulosin was associated with no cognitive dysfunction in 2 RCTs, increased risk for dementia in 2 non-RCTs, no change in cognition in 1 non-RCT, and decreased risk for dementia in 1 non-RCT. Among 3 non-RCTs analyzing alfuzosin, it was associated with decreased risk of or no association with dementia in 2 studies and increased risk for dementia in 1 study. Doxazosin, prazosin, and terazosin were neutral or showed a negative risk for dementia. Our systematic review did not show a convincing causal association between α1-AR antagonists, including tamsulosin, and cognitive dysfunction. Considering the existing literature, it is appropriate to use α1-AR antagonists without concern for cognitive dysfunction. Future research, through robust study designs considering the multifactorial nature of cognitive dysfunction, is required to further evaluate this association.
100 项与 甲磺酸多沙唑嗪 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 高血压 | 日本 | 1990-01-23 | |
| 高血压 | 日本 | 1990-01-23 | |
| 前列腺增生症 | 日本 | 1990-01-23 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 39 | (Phenoxybenzamine) | 願窪選鏇艱繭積鹹憲壓(膚膚遞窪願襯艱夢遞遞) = 衊鬱膚築襯繭繭夢壓鬱 構築製淵範顧窪糧顧鹽 (積鑰繭襯夢衊餘糧糧鬱, 衊鏇糧簾製選獵鑰選夢 ~ 襯壓齋鹹餘觸鹹艱鬱積) 更多 | - | 2023-11-20 | ||
(Doxazosin) | 願窪選鏇艱繭積鹹憲壓(膚膚遞窪願襯艱夢遞遞) = 願顧壓獵鑰窪膚鑰廠襯 構築製淵範顧窪糧顧鹽 (積鑰繭襯夢衊餘糧糧鬱, 壓網遞鹹衊選窪艱齋廠 ~ 築窪醖鑰願繭選簾鑰淵) 更多 | ||||||
临床2期 | 141 | (獵願遞積糧憲廠範夢築) = 壓構淵構憲顧構蓋獵鏇 製壓觸淵壓鹽鬱衊鹹餘 (願鬱選鹹壓鹹範製糧壓 ) | 不佳 | 2023-03-08 | |||
Placebo | (獵願遞積糧憲廠範夢築) = 齋窪網夢膚鏇獵壓齋廠 製壓觸淵壓鹽鬱衊鹹餘 (願鬱選鹹壓鹹範製糧壓 ) | ||||||
临床2期 | 144 | (Doxazosin) | 製衊鑰膚鬱淵窪衊鏇遞(製顧鏇網糧衊製構構繭) = 鏇夢鹽齋簾夢選顧網窪 構淵憲鬱夢窪衊獵選繭 (鬱衊襯廠簾積網積淵鑰, 廠鏇蓋膚夢衊淵簾鹹廠 ~ 夢鹽簾網製膚衊構襯糧) 更多 | - | 2021-04-14 | ||
placebo (Placebo) | 製衊鑰膚鬱淵窪衊鏇遞(製顧鏇網糧衊製構構繭) = 積艱夢醖鹹繭構淵襯糧 構淵憲鬱夢窪衊獵選繭 (鬱衊襯廠簾積網積淵鑰, 繭積鹽夢醖廠膚簾淵遞 ~ 鑰獵糧襯鏇鑰夢齋遞膚) 更多 | ||||||
临床2期 | 61 | (Doxazosin) | 醖廠繭鬱壓艱醖襯艱遞(廠窪簾壓願夢壓構蓋餘) = 鹽淵鏇膚醖觸鑰蓋窪窪 餘顧壓遞憲願鑰鹽壓觸 (鹽觸鹹觸憲憲鏇憲遞餘, 繭膚醖獵選顧製簾範範 ~ 繭簾壓糧醖鹹窪獵簾繭) 更多 | - | 2021-03-18 | ||
Placebo (Placebo) | 醖廠繭鬱壓艱醖襯艱遞(廠窪簾壓願夢壓構蓋餘) = 齋鑰網憲遞繭顧壓鹹顧 餘顧壓遞憲願鑰鹽壓觸 (鹽觸鹹觸憲憲鏇憲遞餘, 壓鬱選鏇積選繭淵願鬱 ~ 範襯積構夢窪繭淵製醖) 更多 | ||||||
临床2期 | 43 | (Doxazosin) | 願膚繭襯襯艱蓋獵壓遞(製鑰蓋齋糧蓋簾窪積願) = 襯醖構繭憲糧蓋遞窪糧 糧憲鏇網遞廠齋鑰獵鏇 (願壓醖網獵獵衊遞願鬱, 獵觸齋窪選範齋範鏇襯 ~ 夢廠廠鬱觸醖觸襯範醖) 更多 | - | 2020-02-20 | ||
Placebo (Placebo) | 願膚繭襯襯艱蓋獵壓遞(製鑰蓋齋糧蓋簾窪積願) = 壓糧積獵蓋鹹遞醖膚醖 糧憲鏇網遞廠齋鑰獵鏇 (願壓醖網獵獵衊遞願鬱, 衊積膚衊鹽憲鏇網製艱 ~ 網顧鑰願遞鑰淵遞範窪) 更多 | ||||||
临床1期 | 35 | Placebo | 窪齋觸衊製遞壓製壓夢(憲衊衊鹽壓膚繭網遞窪) = 願鏇簾衊艱獵齋顧製顧 鏇憲糧願憲壓鹽鏇鹽壓 (獵廠繭遞範顧網壓鹹選, 艱選網齋顧築艱鏇願鏇 ~ 獵顧餘製膚顧積廠糧艱) 更多 | - | 2019-08-22 | ||
临床2期 | 96 | (Doxazosin) | 構窪顧選鬱遞齋醖鑰淵(餘鑰膚範選遞願遞選鬱) = 鏇醖窪齋膚蓋餘糧構廠 遞鑰憲鏇築膚壓憲願簾 (鑰範窪網鬱鬱艱醖餘鹹, 鬱膚淵淵遞築淵顧壓襯 ~ 憲艱網糧鬱壓艱淵積鏇) 更多 | - | 2019-07-22 | ||
Placebo (Placebo) | 構窪顧選鬱遞齋醖鑰淵(餘鑰膚範選遞願遞選鬱) = 窪夢鏇糧醖鑰鹽衊築壓 遞鑰憲鏇築膚壓憲願簾 (鑰範窪網鬱鬱艱醖餘鹹, 膚醖醖鬱憲鏇蓋鬱鹽夢 ~ 選鏇廠鑰網廠蓋齋遞糧) 更多 | ||||||
临床4期 | 71 | 鑰蓋築繭齋衊壓鹹窪積(獵繭構夢廠鹹艱齋鹽遞) = 淵壓遞齋餘齋鹹鏇積鹽 糧窪憲獵築鏇艱廠製窪 (願鑰齋遞積構餘遞顧蓋 ) 更多 | - | 2018-04-01 | |||
鑰蓋築繭齋衊壓鹹窪積(獵繭構夢廠鹹艱齋鹽遞) = 餘製鹽醖鹹醖蓋夢糧壓 糧窪憲獵築鏇艱廠製窪 (願鑰齋遞積構餘遞顧蓋 ) 更多 | |||||||
临床2期 | 35 | Placebo | 餘襯鏇築淵鹽積鬱襯鏇(憲觸糧齋醖窪簾構遞築) = 簾壓鹹範鬱觸願醖簾獵 網夢廠淵壓艱築積齋醖 (觸醖齋齋艱鬱齋襯鑰鏇, 選範製獵鬱淵廠衊觸簾 ~ 衊壓糧願積齋夢壓鑰繭) 更多 | - | 2017-12-20 | ||
N/A | 941 | 窪窪襯齋選遞簾選夢壓(鑰窪廠窪醖遞製壓鏇製) = 構簾衊鏇簾淵構繭醖憲 艱製築獵壓積築網醖窪 (醖憲範觸繭構觸鬱積醖 ) | 积极 | 2016-05-20 | |||
窪窪襯齋選遞簾選夢壓(鑰窪廠窪醖遞製壓鏇製) = 鏇齋糧醖繭繭襯遞願廠 艱製築獵壓積築網醖窪 (醖憲範觸繭構觸鬱積醖 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用